Mirja Rotinen

Pamplona, NC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

ONECUT2: a validated drug target and lineage plasticity driver in prostate cancer and other malignancies.

ONECUT2: a validated drug target and lineage plasticity driver in prostate cancer and other malignancies.

Journal: Endocrine-related cancer

Published: July 22, 2025

ONECUT2 reprograms neuroendocrine fate and is an actionable therapeutic target in small cell lung cancer.

ONECUT2 reprograms neuroendocrine fate and is an actionable therapeutic target in small cell lung cancer.

Journal: Molecular medicine (Cambridge, Mass.)

Published: January 08, 2025

ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity.

ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: May 03, 2024

ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer.

ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer.

Journal: Nucleic acids research

Published: February 02, 2024

Actionable Driver Events in Small Cell Lung Cancer.

Actionable Driver Events in Small Cell Lung Cancer.

Journal: International journal of molecular sciences

Published: November 20, 2023

ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.

ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.

Journal: bioRxiv : the preprint server for biology

Published: October 31, 2023

Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.

Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.

Journal: International journal of molecular sciences

Published: August 17, 2023

Scaffold attachment factor B1 regulates androgen degradation pathways in prostate cancer.

Scaffold attachment factor B1 regulates androgen degradation pathways in prostate cancer.

Journal: American journal of clinical and experimental urology

Published: August 20, 2021

Cutting down on lung cancer: Ecliptasaponin A is a novel therapeutic agent.

Cutting down on lung cancer: Ecliptasaponin A is a novel therapeutic agent.

Journal: Annals of translational medicine

Published: August 15, 2020

"Defining the Independence of the Liver Circadian Clock" & "BMAL1-Driven Tissue Clocks Respond Independently to Light to Maintain Homeostasis".

"Defining the Independence of the Liver Circadian Clock" & "BMAL1-Driven Tissue Clocks Respond Independently to Light to Maintain Homeostasis".

Journal: Frontiers in neuroscience

Published: November 05, 2019

27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells.

27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells.

Journal: Molecular cancer research : MCR

Published: September 24, 2019

ONECUT2 as a new therapeutic target in androgen receptor-indifferent prostate cancer.

ONECUT2 as a new therapeutic target in androgen receptor-indifferent prostate cancer.

Journal: Translational cancer research

Published: September 11, 2019

Showing 1-12 of 18

Last Updated: 09/26/2026